Because of its durability and patency, the left internal mammary artery (LIMA) is preferentially used to bypass obstructive lesions in the left main coronary artery (LMCA) and/or the left anterior descending coronary artery (LAD). The long-term patency of the LIMA graft is determined by several factors, principal among them being the dynamic competition between flow through the internal mammary artery graft and the LAD. We report a patient with LMCA stenosis and a well-functioning and mature LIMA graft, who after percutaneous intervention of the LMCA and normalized antegrade flow in the LAD, developed atresia of a large caliber LIMA graft.

Download full-text PDF

Source

Publication Analysis

Top Keywords

internal mammary
12
mammary artery
12
lima graft
12
left internal
8
artery graft
8
graft percutaneous
8
percutaneous intervention
8
left main
8
coronary artery
8
artery
5

Similar Publications

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Cancer Commun (Lond)

January 2025

Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.

Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.

View Article and Find Full Text PDF

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

Clin Breast Cancer

December 2024

Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.

Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.

Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.

View Article and Find Full Text PDF

The Role of Positron Emission Tomography Imaging in Breast Implant Illness.

Plast Reconstr Surg Glob Open

January 2025

From the Section General Internal Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Background: Explantation often alleviates symptoms in women with breast implant illness. However, persistent complaints in some cases may be linked to persistent silicone-induced inflammation from residual silicone particles. Positron emission tomography (PET) imaging could potentially detect this inflammation.

View Article and Find Full Text PDF

In coronary artery bypass grafting (CABG), the use of the left internal mammary artery (LIMA) is considered the gold standard. The conventional technique of using electrocautery for LIMA harvesting is associated with adverse events. In this study, we used a different technique that combined carbon dioxide with electrocautery to harvest LIMA and compared it with the conventional electrocautery method.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!